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Thesis Chair: Humberto López Castillo, M.D., Ph.D. 
  
ii 
ABSTRACT 
While the adverse health risks associated with smoking have been well-documented, few 
studies have examined the cardiovascular outcomes associated with secondhand smoking. The 
purpose of the study was to assess the distributions and association of cardiovascular diseases 
(CVDs) in nonsmokers exposed to secondhand smoke (SHS). Data were extracted from the 
National Health and Nutrition Examination Survey (NHANES) 2015-2016 cycle. Self-reported 
smoking status and cotinine levels were used to identify exposure groups (smokers, nonsmokers, 
and secondhand smokers), and medical history of several cardiovascular diseases such as 
coronary heart diseases and stroke were also collected via self-report survey. The association 
between exposure to SHS and seven cardiovascular outcomes were analyzed using chi-square 
analysis and odd ratios (OR) with 95% confidence intervals (CIs) were calculated using two 
logistic regression models. The data included 5,709 subjects including 18.5% smokers, 23.6% 
secondhand smokers, and 57.9% nonsmokers. There was statistically significant association 
between exposure to SHS and only two out of seven cardiovascular outcomes, hypertension (OR 
1.554, 95% CI [1.066, 2.265]) and cholesterol levels (OR 1.213, 95% CI [1.017, 1.446]). This 
study is one of the first to determine an association between SHS and seven cardiovascular 
outcomes, thus highlighting the importance of reducing SHS exposure and can be used for 
further research on SHS and cardiovascular health. 
Key words: Cardiovascular disease, cardiovascular health, secondhand smoke, passive 
smoking, environmental tobacco smoke, hypertension, cholesterol levels. 
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INTRODUCTION 
Statement of the Problem 
According to the World Health Organization (WHO), over one-third of all people are 
regularly exposed to secondhand smoke (SHS) across the world, including 40% of children, 33% 
of male nonsmokers, and 35% of female nonsmokers (World Health Organization, n.d.). 
Additionally, the Centers for Disease Control and Prevention (CDC) estimated that, even with 
tobacco bans in public places, 58 million people—roughly one in four nonsmokers—were 
exposed to SHS during 2013-2014 (Tsai et al., 2018). Previous work has shown that more than 
20 million Americans have died due to causes related to SHS, including nearly 2.5 million who 
died due to lung cancer or cardiovascular diseases (CVDs) (Tsai et al., 2018; U.S. Department of 
Health and Human Services, 2014). Exposure to SHS also increase the risk of stroke by 20% to 
30%. Additionally, SHS may even lead to reproductive concerns, such as low birth weight (U.S. 
Department of Health and Human Services, 2014). As nonsmokers exposed to SHS are more 
likely to develop these outcomes, it is critical to understand the relation between SHS exposure 
and CVDs. 
Also known as passive smoking or environmental tobacco smoke, SHS, is the inhalation 
of burning tobacco products—such as cigarettes, pipes, hookah, or e-cigarettes by people other 
than the active smoker (Centers for Disease Control and Prevention, 2018c; U.S. Department of 
Health and Human Services, 2014). Secondhand smoke is a known cause of many diseases in 
adults and children, including stroke, nasal irritation, lung cancer, and CVDs. Exposure to SHS 
was highest among people who have respiratory diseases, CVDs, and cancer (Asfar et al., 2019). 
Additionally, children aged 3 to 11 years have the highest exposure to SHS, including 67.9% of 
non-Hispanic blacks, 37.2% of non-Hispanic whites, and 29.9% of Mexican Americans (Homa 
2 
et al., 2015). Few studies have examined the exposure to SHS and different biomarkers of CVDs, 
but results suggest a direct relation (Saxena, Liang, Muhammad-Kah, & Sarkar, 2017; Venn & 
Britton, 2007). None of these studies, however, examined the different types of CVDs in 
nonsmokers exposed to SHS, which would be critical, given the fact that heart diseases are the 
leading cause of death in the United States (CDC). Therefore, the purpose of this study is to 
assess the distribution of CVDs in nonsmokers exposed to SHS. It is hypothesized that 
individuals who are nonsmokers, but exposed to secondhand smoke, will have similar likelihood 
of having CVDs compared to firsthand smokers. The following question will guide the study’s 
analysis: 
Do nonsmokers who have an exposure to SHS have similar likelihood of developing 
CVDs compared to firsthand smokers? 
Literature Review 
Secondhand Smoke: Overview 
Although smoking among U.S. adults has declined from 20.9% in 2005 to 15.5% in 
2016, it is still an ongoing epidemic in the United States (Centers for Disease Control and 
Prevention, 2018d). According to the Surgeon General, if smoking rates remain unchanged, 5.6 
million Americans younger than 18 years of age are projected to die due to smoking-related 
illness (U.S. Department of Health and Human Services, 2014). 
Exposure to SHS is harmful to health and has been linked to several fatal illnesses among 
infants and adults. Although exposure to SHS has declined by over 50% (25.3% in 2011-2012 
from 52.5% in 1999-2000), 58 million people—roughly one in four nonsmokers—were still 
exposed to SHS during 2013-2014 (Homa et al., 2015; Tsai et al., 2018; U.S. Department of 
Health and Human Services, 2014). In 2006, more than 42,000 Americans died from illnesses 
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related to SHS exposure, including more than 41,000 adults and nearly 900 infants (Max, Sung, 
& Shi, 2012). Additionally, exposure to SHS causes significantly more death due to CVDs than 
due to lung cancer (U.S. Department of Health and Human Services, 2014). In 2005-2009, 32% 
of all deaths from CHD were attributed to smoking and exposure to SHS (U.S. Department of 
Health and Human Services, 2014). Since there is still a large number of people exposed to SHS 
and are more likely to develop CVDs compared to unexposed individuals, more research 
assessing CVDs in nonsmokers who are exposed to SHS is warranted. 
Secondhand Smoke: Related Conditions 
While SHS does not have the same elevated risk levels as firsthand smoking, SHS 
exposure is still not risk free. According to report of the Surgeon General, in adults, exposure to 
SHS can increase the risk of stroke, nasal irritation, lung cancer, coronary heart disease (CHD), 
and reproductive effect in women such as lower low birthweight (U.S. Department of Health and 
Human Services, 2014). The CDC also states that nonsmokers who are exposed to SHS increase 
their risk for developing lung cancer by 20% to 30% and SHS causes more than 7,300 lung 
cancer–related deaths each year in the United States (Centers for Disease Control and 
Prevention, 2018a). 
Moreover, nonsmokers who are exposed to SHS increase their risk of developing CVDs 
by 25% to 30%, leading to approximately 34,000 premature deaths from heart diseases every 
year in the United States (Centers for Disease Control and Prevention, 2018a). Also, inhaling 
SHS can have immediate effects on blood platelets and the lining of blood vessels since 
individuals exposed to SHS are still inhaling many types of toxins, which increase the risk of 
having heart attack (Centers for Disease Control and Prevention, 2018a). People exposed to SHS 
share similar risks with smokers in developing CVDs, which can be expensive and fatal if not 
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diagnosed and treated early (U.S. Department of Health and Human Services, 2014). 
Unfortunately, many people exposed to SHS are not aware of their increased risk of developing 
CVDs and, thus, more research assessing the relation between CVDs and exposure to SHS in 
nonsmokers is warranted. 
Evaluation Exposure to Secondhand Smoke Using Biological Markers 
Tobacco smoke consists of thousands of chemicals, including carbon dioxide, carbon 
monoxide, nicotine, carbonyls, hydrocarbons, nitrogen oxides, pyridines, and ammonia 
("Evaluating Exposure to Secondhand Smoke," 2010). Nonsmokers exposed to SHS are 
subjected to two components of SHS: side-stream smoke (85%), which is the smoke emerging 
from the burning tip of the cigarette, and main-stream smoke (15%), which is the smoke inhaled 
by a smoker when puffing on a cigarette (Kritz, Schmid, & Sinzinger, 1995). Compounds about 
three to four times more toxic are emitted through side-stream compared to main-stream smoke 
("Evaluating Exposure to Secondhand Smoke," 2010; Schick & Glantz, 2005). Additionally, 
both side- and main-stream smoke are capable of generating oxidative stress–inducing 
chemicals—such as acrolein, xanthine oxidase, and oxides of nitrogen, which may mediate many 
of the smoke effects on the cardiovascular system ("Experimental Studies Relevant to the 
Pathophysiology of Secondhand Smoke," 2010). Thus, the toxicity that nonsmokers are exposed 
to via SHS can leads to increased risk of different CVDs. 
Nicotine is present in all tobacco products, as well as in some foods although at very low 
concentrations (Benowitz, 1999). Once nicotine enters the body, it will be converted to cotinine, 
which is then converted to trans-3'-hydroxycotinine by the hepatic enzyme cytochrome P450 
2A6 (Hukkanen, Jacob, & Benowitz, 2005). About 70% to 80% of nicotine is converted to 
cotinine, which makes it the primary metabolite ("Evaluating Exposure to Secondhand Smoke," 
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2010; Hukkanen et al., 2005). Cotinine can be measured in blood, saliva, urine, and other 
biologic fluids. The average half-life of cotinine (16 hours) in plasma is 8 times longer than 
nicotine (2 hours). Additionally, the concentrations of cotinine in blood and saliva are highly 
similar. However, urinary cotinine concentrations are four to five times higher than those in 
blood or saliva, which makes urine a more sensitive matrix for detection of low exposure of 
cotinine (Benowitz, Bernert, Caraballo, Holiday, & Wang, 2009; Hukkanen et al., 2005). 
Therefore, cotinine concentrations are more stable than nicotine due to the longer half-life and 
the ability to measure it in different body fluids, making it the preferred biomarker of smoke 
exposure to SHS and to differentiate smokers from nonsmokers. 
Cardiovascular Diseases Due to Secondhand Smoke Exposure 
Effects of Secondhand Smoke at the Cellular Level 
Endothelial Dysfunction 
The normal function of endothelial cells is to promote vasodilation and inhibit thrombosis 
and atherosclerosis, which is mediated by the release of nitric oxide (NO) (Glantz & Parmley, 
2001). However, a dysfunction in the endothelial cells can lead to the development of 
atherosclerosis—a build-up of cholesterol plaque in the arterial walls. Otsuka and colleagues 
(2001) conducted a cross-sectional study to determine the acute effects of SHS on coronary 
circulation in healthy nonsmokers, Japanese men, found that only 30 minutes of exposure to SHS 
can cause endothelial dysfunction of the coronary circulation in nonsmokers (Otsuka et al., 
2001). Additionally, there was a similar endothelial-dependent vasodilation impairment between 
active smokers and people who had exposure to SHS. 
Similar to the previous study by Otuska et al., (2001), a more recent study investigated 
endothelial cells and the flow-mediated dilation by sampling endothelial cells in three groups: 1) 
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active smokers; 2) individuals exposed to SHS; and 3) nonsmokers. The study confirmed that 
SHS exposure increases vascular inflammation and reduces endothelial NO synthase to the same 
levels as an active smoker (Adams et al., 2015). Even though these studies were published more 
than ten years apart, they indicate direct toxic effects of SHS exposure on the endothelial cells, 
which can lead to more serious types of CVDs. 
Inflammation 
Tobacco smoke produces systemic inflammation via an increase of oxidative stress 
mediators and the reduction of NO bioavailability (Ambrose & Barua, 2004). There are many 
biological markers for inflammation, including C reactive protein (CRP), white blood cell 
(WBC) count, fibrinogen, and blood viscosity (Ambrose & Barua, 2004; Jefferis et al., 2010). 
One of the essential biological markers for inflammation for CVDs is CRP—a hepatic protein 
produced in response to acute and chronic inflammation. At population level, a high-sensitive 
CRP (hs-CRP) test is used to assess CVD risk. 
Multiple studies have examined the relation between SHS and inflammation, and all of 
them have shown a positive correlation between SHS and inflammation (Jefferis et al., 2010; 
Venn & Britton, 2007). For example, in a cross-sectional, population-based study of more than 
5,000 participants, investigators looked at multiple biological markers for inflammation, 
including CRP, WBC count, triglycerides, fibrinogen, and blood viscosity (Jefferis et al., 2010). 
Compared to nonsmokers, participants who were current smokers or nonsmokers with SHS 
exposure had higher circulating levels of CRP, WBC count, triglycerides, and fibrinogen. The 
authors concluded that inflammatory markers related to CVDs risk showed an independent 
association with SHS exposure in a similar way as active smoking (Jefferis et al., 2010). 
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Furthermore, using data from the third National Health and Nutrition Examination 
Survey (NHANES III), Venn & Britton (2007) examined the relationship between SHS and 
inflammation levels using participants’ cotinine levels. They found that participants exposed to a 
small amount of SHS had increased levels of two biological markers for CVDs, which were 
fibrinogen and homocysteine (Venn & Britton, 2007). However, there was no evidence that CRP 
increased in relation to cotinine levels (Venn & Britton, 2007). Yet, a different study that also 
used NHANES III data to examine the relation between SHS and CRP levels in never smokers 6-
18 years old found that there was an association between the increase in serum cotinine and an 
increase in CRP (Wilkinson, Lee, & Arheart, 2007). In conclusion, there is strong evidence of a 
relation between exposure to SHS and an increase in CVD inflammation biomarkers. 
Lipid Profile 
Secondhand smoke exposure may promote atherosclerosis due to its effects on 
endothelial cells and lipid profile. In an animal study, investigators used a mouse model and 
smoking systems that closely simulated exposure of SHS. The mice had moderate lipid levels 
that mimicked human lipid levels that led to atherosclerosis plaque formation. They found that 
exposure to SHS decreased plasma high-density lipoprotein (HDL) cholesterol levels in the 
blood and decreased the ratio between HDL and low-density lipoprotein (LDL) cholesterol, HDL 
cholesterol and triglycerides, and HDL cholesterol and total cholesterol (Yuan et al., 2007). In a 
similar study with humans, investigators took blood samples from 10 nonsmokers (5 male and 5 
female) with normal lipid levels. Then subjects were exposed to 30 minutes of SHS. They found 
that exposure to SHS accelerated lipid peroxidation and LDL cholesterol modification. 
Additionally, there was an association between an increased accumulation of LDL cholesterol in 
human macrophages (Valkonen & Kuusi, 1998). 
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Furthermore, a study examined 12 healthy, nonsmoker males to determine the influence 
of a 6-hour exposure to SHS on lipoprotein levels. Baseline blood samples were drawn before 
SHS exposure and after 6, 8, 16, and 24 hours of SHS exposure. Investigators found that 
exposure to SHS can reduce HDL cholesterol levels by 18%. Additionally, there was a negative 
impact on HDL cholesterol levels and remained depressed for at least 24 hours (Moffatt, 
Chelland, Pecott, & Stamford, 2004). Therefore, short-term exposure to SHS led to inflammation 
and an imbalance in the lipid profile, which leads to lipid accumulation in the liver and the blood 
vessels of the heart that leads to more severe types of CVDs. 
Thrombosis 
Thrombosis is the formation of a thrombus—a blood clot, within a blood vessel. 
Thrombocytes are cell derivatives that circulate in the blood and play a role in thrombosis. 
Secondhand smoke exposure can cause alteration in the function of platelets and antithrombotic, 
prothrombotic, and fibrinolytic factors (Ambrose & Barua, 2004). Additionally, SHS exposure 
may decrease availability of platelet-derived NO and decrease platelet sensitivity to exogenous 
NO, leading to increased activation and adhesion (Ambrose & Barua, 2004; Ichiki, Ikeda, 
Haramaki, Ueno, & Imaizumi, 1996). Increased platelet adhesion will increase thrombus 
formation, which disrupts the endothelium, speed progression of atherosclerosis, and increase 
risk of ischemic heart disease (Law & Wald, 2003). 
A study by Burghuber et al (1986) concurs with the findings reported by Ambrose & 
Baru (2004) regarding platelet sensitivity and SHS exposure. This study had 9 healthy male 
nonsmokers sit in a room for 20 minutes where 30 heavy band cigarettes had just been smoked. 
Blood was drawn before and 15 minutes after participants had been exposed to SHS. 
Investigators found that platelets sensitivity nonsmokers decreased due to SHS exposure. 
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Therefore, exposure to SHS decrease platelets sensitivity, which can increase platelets activation 
and thrombosis that can leads to more severe types of CVDs such as CHD and stroke. 
Hypertension 
Secondhand smoke exposure shows multiple effects on blood pressure; however, the 
literature suggests these effects may primarily occur in males (Flouris, Metsios, Jamurtas, & 
Koutedakis, 2008). For example, in a study that examined the effects of exposure to SHS on 
blood pressure, 14 men and 14 women were exposed to a simulated SHS in bar-restaurant 
environment for 60 minutes. Even though the study included a small sample size, the investigator 
found that systolic blood pressure significantly increased in men but not in women (Flouris et al., 
2008). Similarly, in a study examined the effects of a 60-minute exposure to SHS on blood 
pressure and aortic pressure waveform in 10 healthy men, 11 women, and 12 controls (6 men, 
6 women). The investigators found that, in men only, there was an association between SHS and 
increased brachial and aortic systolic blood pressure after 60 minutes. About half of the blood 
pressure increase happened at 15 minutes and it reached steady state after 30 minutes. 
Additionally, the authors found an increase in arterial stiffness, which could be the cause of 
increased blood pressure. However, brachial and aortic diastolic blood pressure and heart rate did 
not change in either male or females subjects (Mahmud & Feely, 2004). Therefore, an acute 
exposure to SHS has a deleterious effect on blood pressure in healthy males but not females. 
Coronary Heart Disease 
Also known as coronary artery disease or ischemic heart disease, CHD is the most 
common type of heart disease in the United States, killing more than 365,900 people in 2017. 
Additionally, about 18.2 million adults age 20 and older have CHD (Centers for Disease Control 
and Prevention, 2019a). Coronary heart disease is caused by plaque buildup in the wall of the 
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coronary artery of the heart. Plaque is made up of deposits of cholesterol and overtime it can 
become atherosclerosis. 
The effect of SHS on the risk of CHD is controversial. Although several meta-analyses 
have concluded that exposure to SHS increases the risk of CHD by 25% among nonsmokers, a 
study by Enstrom and Kabat (2006) disputed the results of these studies, suggesting that 
selection bias of results may have skewed findings (Enstrom & Kabat, 2006). Their study 
focused on the United States cohort studies which provided the most available evidence about 
the association between CHD and SHS. They concluded that there is about 5% increase risk of 
death from CHD in nonsmokers exposed to SHS (Enstrom & Kabat, 2006). Similarly, in a 
different meta-analysis that reviewed epidemiological studies published between 1966 and 1998, 
He and colleagues (1999) looked at 10 prospective cohort studies and 8 case-control studies on 
the association between SHS and CHD. This study found that SHS exposure is associated with a 
greater risk of CHD (relative risk [RR] 1.25; 95% confidence interval [CI] [1.17, 1.32]) 
compared to unexposed nonsmokers. Specifically, there was a, 21% increased risk of CHD in 
cohort studies, and a 51% increased risk of CHD case control studies (J. He et al., 1999).  
Angina 
Also known as angina pectoris and acute coronary syndrome, angina is chest pain or 
discomfort that occurs when the heart muscle does not get enough oxygenated blood. It is a 
common symptom of CHD, which narrows the blood vessels to limit blood flow to the heart and 
increases the risk of a heart attack (National Heart Lung and Blood Institute, n.d.). Early work by 
Aronow (1978) examined the association between angina and exposure to SHS in a sample of 
ten male patients who experienced exercise-induced angina, after exposure to the smoke of 15 
cigarettes within two hours in a ventilated room and unventilated room. The study found that 
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exposure to SHS lead subjects to elevated venous carboxyhemoglobin, increased heart rate, 
systolic and diastolic blood pressure while resting, and decreased heart rate and systolic blood 
pressure at angina. Additionally, the study concluded that exposure to SHS aggravates angina 
(Aronow, 1978). However, this is the only study that has been done to examine the association 
between angina and exposure to SHS. Thus, it is a reason for more research to be done to 
examine SHS and chronic angina. 
Heart Attack 
Heart attack, also called a myocardial infarction (MI), happens when a part of the 
myocardium does not get enough blood. The leading cause of death in the United States is heart 
diseases which can lead to heart attack. In the United States, about 805,000 Americans have a 
heart attack every year, and about one in five heart attacks is silent—the person is not aware of it 
(Centers for Disease Control and Prevention, 2019a). It is unknown, however, the percentage of 
heart attacks that may have been a result of SHS, as SHS exposure can cause cellular dysfunction 
through endothelial dysfunction, inflammation, and thrombosis, which may lead to more serious 
heard diseases, and result in a heart attack. 
Based on this findings, results from multiple studies support the suggestion that exposure 
to SHS increases the risk of a heart attack across the world (Attard et al., 2017; Iversen, 
Jacobsen, & Lochen, 2013). For example, Iversen and collaborators (2013) looked at active and 
passive smoking as a risk factor for heart attack in an 11-year follow-up of 11,762 men and 
13,206 women using data from the Tromsø Study in Norway. Out of 453 cases of heart attack in 
women, 20% of these cases were attributed to SHS. Additionally, the study concluded that 
women who are living with a smoker for 30 years or more after the age of 20 had increased risk 
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of heart attack by 40% due to SHS. However, there was no effect of living with a smoker in men 
(Iversen et al., 2013). 
Similarly, the Maltese Acute Myocardial Infarction (MAMI) case-control study examined 
423 cases with a first heart attack and 465 population controls. The study used a questionnaire 
and morning fasting blood samples to investigate the effect of SHS and the risk of a heart attack. 
The study concluded that exposure to SHS increased the risk of heart attack, and reported that 
there was a higher risk of heart attack from SHS in the home rather than in public settings 
(Attard et al., 2017). These findings suggest that exposure to SHS in nonsmokers does increase 
the risk of a heart attack, and that this risk may be particularly high in nonsmokers living in 
households with other smokers. 
Stroke 
Stroke is one of the leading causes of death in the United States. Every year, stroke kills 
about 140,000 people in the United States and 8,000 of those deaths due to SHS exposure. 
Additionally, about 87% of all strokes are ischemic stroke—when blood flow to the brain is 
blocked, usually by a thrombus (Centers for Disease Control and Prevention, 2019c, 2020). The 
current literature suggests an increased risk for stroke when there is SHS exposure. For example, 
in a national population-based case-control study in China, investigators used the Nationwide 
Retrospective Mortality Survey, conducted from 1989 through 1991. The study included 
16,205 cases (12,579 with hemorrhagic stroke and 3626 with ischemic stroke). The study 
concluded that, compared with nonsmokers without any exposure to SHS, exposure to SHS 
significantly increased the likelihood of death by 10% for all strokes (odds ratio [OR] 1.10; 95% 
CI [1.05, 1.16]), by 10% for hemorrhagic stroke (OR 1.10; 95% CI [1.04, 1.16]), and by 12% for 
ischemic stroke (OR 1.12; 95% CI [1.03, 1.23]), (Hou et al., 2017). 
13 
Furthermore, a meta-analysis included 14 studies involving 30,3134 subjects and 
4,050 stroke events, compared to smokers and nonsmokers with exposure to SHS for the risk of 
stroke. The study concluded that smokers had an overall significantly increased likelihood of 
stroke compared with nonsmokers (OR 1.61; 95% CI [1.34, 1.93]). There was a statically 
significant difference by sex among males (OR 1.54; 95% CI [1.11, 2.13]) and in females (OR 
1.88; 95% CI [1.45, 2.44]). Additionally, exposure to SHS significantly increased the overall 
likelihood of stroke by 45% (OR 1.45; 95% CI [1.0, 2.11]) (Pan et al., 2019). All 14 studies 
found that there was an association between both smoking and exposure to SHS with increased 
risk of stroke (Pan et al., 2019). Therefore, exposure to SHS in nonsmokers increases the risk of 
stroke. 
Heart Failure 
Heart failure happens when the heart cannot pump enough blood to support other organs 
in the body. There are about 6.5 million adults with heart failure in the United States and it costs 
the nation about $30.7 billion in 2012 (Centers for Disease Control and Prevention, 2019b). 
Multiple studies examined the association of mortality with SHS exposure for patients with heart 
failure. For example, in one study that used NHANES III, there was a total of 19,592 adults, 
including 572 participants who had a diagnosis of heart failure, included in their analysis. The 
study looked at the household SHS exposure and mortality status of participants from the 2011 
Public-Use Mortality Linked File. After analysis, the investigators concluded that there was an 
association between the household SHS exposure and an increased risk of death among heart 
failure patients (X. He, Zhao, He, Dong, & Liu, 2019). 
Similarly, in a longitudinal cohort study, a questionnaire and urinary cotinine levels were 
used to define people with SHS to examine its impact on heart failure in 197 participants. After a 
14 
median follow up of 4.3 years, the mean mortality rate was 9 deaths per 100 patient-years (95% 
CI [8, 11]), and they concluded that SHS exposure is associated with increase in mortality of 
patients with heart failure (Psotka, Rushakoff, Glantz, De Marco, & Fleischmann, 2020). 
Therefore, exposure to SHS can increase the mortality rates of patients with heart failure but it 
does not increase the risk of heart failure itself. 
Overall, the literature demonstrates a meaningful relation between exposure to SHS and 
CVDs. The present study addresses a gap in the literature by using a larger sample size from a 
national survey to generate more generalizable results that pertain to cardiovascular outcomes in 
nonsmokers exposed to SHS. 
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METHODS 
Participants 
Data in this study were obtained from the National Health and Nutrition Examination 
Survey (NHANES) 2015-2016 cycle, which targeted the noninstitutionalized United States 
civilian population and is administrated by the National Center for Health Statistics (NCHS), part 
of the CDC. The annual NHANES collects information on a range of topics pertaining to health 
using interviews, physical examination, and laboratory work (Centers for Disease Control and 
Prevention, 2017). Relevant contents to this study include current and former smoking status, 
exposure to SHS, CVDs, disease prevalence, and blood draw used to determine serum cotinine 
levels, among other variables. 
The sample size completing the annual NHANES interviews is approximately 
5,000 individuals of all ages (Centers for Disease Control and Prevention, 2017). Although the 
NHANES has collected data since 1960, this study specifically investigated the sample form the 
years 2015 to 2016, which had 9,971 persons who completed the interview, among which 
9,544 (95.7%) participants completed interview and provided biological specimens. Data 
collected from these years are the most recently published data after the change in the initial 
sample design that happened in 2011, which implemented NHANES to oversample non- 
Hispanic (NH) Asians. Additionally, the oversample subgroups in the 2015-2016 survey cycle 
included: Hispanics, NH black, NH white, and other races, including multiracial backgrounds 
(Centers for Disease Control and Prevention, 2018b). 
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Procedure 
Demographics 
The sample population comprised of 13,164 subjects who answered questions on tobacco 
usage, had recorded laboratory values for serum cotinine in blood, and answered specific 
questions about CVDs. Demographic data included age, gender, and race/ethnicity and were self-
reported by participants. For this study, the sample population was categorized by decades, 
starting at age 10 up to a last group comprising 80 years old and above. The race/ethnicity 
variables were also categorized into six groups: Mexican American, other Hispanic, non-
Hispanic white, non-Hispanic black, non-Hispanic Asian, and other races, including multi-racial. 
Exposure Groups 
Participants were divided into three groups: nonsmokers, nonsmokers exposed to SHS, 
and current smokers (CS). Nonsmokers responded “no” to the question “During the past 5 days, 
including today, did you smoke cigarettes, pipes, cigars, little cigars or cigarillos, water pipes, 
hookahs, or e-cigarettes?” and had blood serum cotinine levels 0.050 ng/ml. Participants 
exposed to SHS responded “no” to the question “During the past 5 days, including today, did you 
smoke cigarettes, pipes, cigars, little cigars or cigarillos, water pipes, hookahs, or e-cigarettes?” 
and had blood serum cotinine levels 0.050 ng/ml. Finally, participants were defined as CS if 
they responded “yes” to the question “During the past 5 days, including today, did you smoke 
cigarettes, pipes, cigars, little cigars or cigarillos, water pipes, hookahs, or e-cigarettes?” and if 
they had blood serum cotinine levels 3.0 ng/ml. Participants must have responded to the 
questions and have blood serum cotinine levels reported to be considered in this study. 
Participants were excluded if they did not answer the questions above or if they did not have a 
blood serum cotinine levels reported. 
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Blood cotinine levels cut-offs were 0.050 ng/ml for nonsmokers and 0.050 ng/ml for 
nonsmokers exposed to SHS. These values were based on methods reported by previous studies 
examining blood cotinine levels in nonsmokers and people exposed to SHS (Agarwal, 2009; 
Fabry et al., 2011). As for CS, the blood cotinine level cut-off was 3.0 ng/ml based on previous 
studies examining blood cotinine levels in CS (Fabry et al., 2011; Saxena et al., 2017). 
Outcomes 
There were 11 questions assessing CVDs among NHANES respondents, including six 
questions from the Blood Pressure & Cholesterol and five questions from the Medical 
Conditions questionnaires. All the answers to these questions were binary (yes/no) and self-
reported. Participants who refused to answer the questions, were not provided with 
questionnaire, or who did not know the answer were excluded from the study. The questions 
from Blood Pressure & Cholesterol questionnaire were: 
– Have you ever been told by a doctor or other health professional that you had hypertension, 
also called high blood pressure? 
– Were you told on 2 or more different visits that you had hypertension, also called high blood 
pressure? 
– Because of your high blood pressure/hypertension, have you ever been told to take prescribed 
medicine? 
– Are you now taking prescribed medicine for high blood pressure? 
– Have you ever been told by a doctor or other health professional that your blood cholesterol 
level was high? 
– To lower your blood cholesterol, have you ever been told by a doctor or other health 
professional to take prescribed medicine? 
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The questions from the Medical Conditions questionnaires were:  
– Has a doctor or other health professional ever told you that you had congestive heart failure? 
– Has a doctor or other health professional ever told you that you had coronary heart disease? 
– Has a doctor or other health professional ever told you that you had angina, also called 
angina pectoris? 
– Has a doctor or other health professional ever told you that you had a heart attack also called 
myocardial infarction? 
– Has a doctor or other health professional ever told you that you had a stroke? 
Statistical Analyses 
Data on demographics, blood serum cotinine levels, questionnaire about blood pressure 
and cholesterol and medical conditions, were downloaded from the CDC website. Each dataset 
was opened and match-merged one-to-one by participant identification number using the 
Statistical Analysis System (SAS) (The SAS Institute; Cary, NC) software. The full dataset was 
then exported to the Statistical Package for Social Sciences (SPSS) software (The IBM 
Corporation; Armonk, NY) for further analyses. 
Chi-square tests were performed to examine the responses to the 11 health questions 
related to CVD by the three groups of interest (i.e., CS, exposed to SHS, nonsmokers). 
Significance level was established at α=.05. 
Additionally, ORs with 95% CIs were calculated using two logistic regression models to 
estimate the strength of association between exposure to SHS and cardiovascular outcomes. 
Model 1 yielded raw ORs and Model 2 was adjusted for gender, race/ethnicity, and age. In both 
models, nonsmokers with no exposure to SHS were used as a reference group and Nagelkerke’s 
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R2 was reported as a measure of model fit. This coefficient can be interpreted as the percentage 
of variance in the CVD outcomes that can be accounted for by the variables in the models. 
Ethical Considerations 
The NHANES is a publicly available dataset without any identifiable information 
available for use by the research community. Therefore, the Institutional Review Board approval 
was not necessary for these secondary analyses. 
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RESULTS 
The sample population comprised of 13,164 subjects who answered questions on tobacco 
usage, had recorded laboratory values for serum cotinine in blood, and answered various 
questions about CVDs. Of the 13,164 subjects in the dataset, 7,455 (56.6%) were excluded 
because they did not complete portions of the questionnaire about tobacco use or CVDs, leaving 
5,709 subjects in the analytic sample. 
Demographic Characteristics 
The demographic data for the study participants is presented in Table 1. 
Table 1. Demographic characteristics of the studied population 
Demographic 
Variables 
Smokers 
(N=1054) 
Secondhand 
smokers 
(N=1347) 
Nonsmokers 
(N=3308) 
Total 
(N=5709) 
χ2 (df)a 
n Col % n Col % n Col % n Col % 
Gender         87.88 (2) 
Male 652 61.9 661 49.1 1498 45.3 2811 49.2  
Female 402 38.1 686 50.9 1810 54.7 2898 50.8  
Age Groups, years         
 
322.79 
(14) 
10-19 56 5.3 356 26.4 626 18.9 1038 18.2  
20-29 191 18.1 206 15.3 350 10.6 747 13.1  
30-39 199 18.9 140 10.4 417 12.6 756 13.2  
40-49 162 15.4 154 11.4 457 13.8 773 13.5  
50-59 200 19.0 142 10.5 419 12.7 761 13.3  
60-69 168 15.9 164 12.2 505 15.3 837 14.7  
70-79 61 5.8 114 8.5 314 9.5 489 8.6  
80 and older 17 1.6 71 5.3 220 6.7 308 5.4  
Race/Ethnicity        
 
361.48 
(10) 
Mexican-
American 
126 12.0 190 14.1% 769 23.2 1085 
19.0 
 
Other Hispanic 107 10.2 137 10.2 493 14.9 737 12.9  
NH white 381 36.1 456 33.9 1048 31.7 1885 33.0  
NH black 329 31.2 404 30.0 456 13.8 1189 20.8  
NH Asian 55 5.2 102 7.6 431 13.0 588 10.3  
Otherb 56 5.3 58 4.3 111 3.4 225 3.9  
Abbreviations: col, column; df, degrees of freedom; NH, non-Hispanic 
aP<0.001 for all χ2 distributions tested. 
bIncludes multi-racial 
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Among smokers, typical participants were males (61.9%), non-Hispanic whites (36.1%), 
in the 50-59 years old (19.0%) and 30-39 years old (18.9%) groups and compared to secondhand 
smokers which had typical participants as females (50.9%), non-Hispanic whites (33.9%), in the 
10-19 years old (26.4%) and 20-29 years old group (15.3%). While among nonsmokers, typical 
participants were females (50.8%), non-Hispanics whites (31.7%), in the 10-19 years old 
(18.9%) group. Chi-square tests for all three demographic characteristics showed that these 
distributions were statistically significantly different from a distribution that would occur at 
random (P<0.001 for the three distributions). 
Cardiovascular Outcomes 
Chi-square tests results for the distribution of the 11 CVD outcomes by the three smoking 
statuses are presented in Table 2. It can be observed that among nonsmokers, nonsmokers 
exposed to SHS, and smokers in the sample, there were statistically significantly different 
distributions for the outcomes of hypertension (P=0.04 for taking prescription and P<0.001 for 
ever been diagnosed), high cholesterol levels (P<0.001), heart failure (P=0.01), and angina 
(P=0.006). However, the distribution by smoking groups was not statistically significantly 
different for the outcomes of CHD, heart attack, and stroke. 
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Table 2. Cardiovascular Outcomes 
Cardiovascular Outcomes N 
χ2 with 2 
df 
P 
Ever told you had high blood pressure 5166 1.674 0.43 
Told had high blood pressure >2 times 1768 1.969 0.37 
Taking prescription for hypertension 1780 6.602 0.04 
Now taking prescribed medicine for high blood pressure 1583 20.211 <0.001 
Doctor told you -high cholesterol level 5135 27.054 <0.001 
Told to take prescription for cholesterol 3809 5.274 0.07 
Ever told had congestive heart failure 4662 8.483 0.01 
Ever told you had coronary heart disease 4648 0.456 0.80 
Ever told you had angina/angina pectoris 4657 10.158 0.006 
Ever told you had heart attack 4664 4.273 0.12 
Ever told you had a stroke 4668 4.010 0.14 
Abbreviation: df, degrees of freedom 
 
Further, we analyzed and tested the chi-square distributions of CVD outcomes by 
demographic characteristics. The results are presented in Table 3 for gender, Table 4 for age 
groups, and Table 5 for race/ethnicity. 
Table 3 displays the chi-square results based on CVD outcomes by gender. There was a 
statistically significantly different distribution for males compared to that of females. Males had 
a statistically significantly higher distribution in the group exposed to SHS and two measures of 
hypertension and high cholesterol while females exposed to SHS only had statistically 
significantly higher distribution angina. There were no other statistically significantly different 
distributions for the rest of the CVDs analyzed. 
Table 4 presents the chi-square results based on CVD outcomes by age groups. There 
were statistically significantly different distributions in hypertension, CHD, angina, heart attack, 
and stroke in individuals between 50-59 years old. While individuals between 40-49 years old 
had statistically significantly different distributions for hypertension, heart failure, angina, and 
stroke. The rest of age groups had two to no CVDs as statistically significant. 
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Additionally, Table 5 displays the chi-square results based on cardiovascular outcomes 
by race/ethnicity groups. Among the six race/ethnicity groups, non-Hispanic blacks tend to have 
most CVDs outcomes (4 out of 7 were statistically significant) while non-Hispanic whites tended 
to have the second most CVDs outcomes (3 out of 7 were statistically significant) and Mexican 
Americans did not have statistically significantly different distribution for any of the seven 
CVDs that were examined in this study. 
Table 3. Cardiovascular Outcomes by Gender 
Cardiovascular Outcomes 
Males  Females 
N χ2 with 
2 df 
P 
 
N χ2 with 
2 df 
P 
Ever told you had high blood pressure 2515 0.695 0.707 
 
2651 1.604 0.448 
Told had high blood pressure >2 times 856 3.548 0.170 
 
912 2.508 0.285 
Taking prescription for hypertension 861 2.353 0.308 
 
919 2.869 0.238 
Now taking prescribed medicine for high 
blood pressure 
744 13.578 0.001 
 
839 5.066 0.079 
Doctor told you -high cholesterol level 2502 29.234 <0.001 
 
2633 5.019 0.081 
Told to take prescription for cholesterol 1805 6.455 0.040 
 
2004 3.827 0.148 
Ever told had congestive heart failure 2267 3.294 0.193 
 
2395 5.244 0.073 
Ever told you had coronary heart disease 2255 0.678 0.713 
 
2393 0.795 0.672 
Ever told you had angina/angina pectoris 2266 3.098 0.212 
 
2391 7.725 0.021 
Ever told you had heart attack 2269 0.279 0.870 
 
2395 5.519 0.063 
Ever told you had a stroke 2272 3.218 0.200 
 
2396 4.555 0.103 
Abbreviation: df, degrees of freedom 
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Table 4. Cardiovascular Outcomes by Age Groups 
 10-19  20-29  30-39  40-49 
Outcome N 
χ2 with 
2 df 
P  N 
χ2 with 
2 df 
P  N 
χ2 with 2 
df 
P  N 
χ2 with 2 
df 
P 
Ever told you had high 
blood pressure 
500 5.170 0.08  747 0.466 0.79  753 18.004 <0.001  773 9.088 0.01 
Told had high blood 
pressure >2 times 
18 0.450 0.80  58 0.214 0.90  143 0.238 0.89  215 0.959 0.62 
Taking prescription for 
hypertension 
19 0.262 0.89  58 0.110 0.95  143 0.966 0.62  215 7.040 0.03 
Now taking prescribed 
medicine for high blood 
pressure 
5 2.917 0.23  25 1.176 0.56  99 0.495 0.78  173 7.364 0.02 
Doctor told you -high 
cholesterol level 
500 1.036 0.60  746 0.152 0.93  752 4.343 0.14  771 0.607 0.74 
Told to take prescription 
for cholesterol 
171 2.636 0.27  370 3.834 0.15  497 5.174 0.08  624 3.823 0.15 
Ever told had congestive 
heart failure 
0 — —  747 — —  756 1.630 0.44  773 6.753 0.03 
Ever told you had 
coronary heart disease 
0 — —  747 — —  756 0.808 0.67  771 0.054 0.97 
Ever told you had 
angina/angina pectoris 
0 — —  747 2.63 0.27  755 3.299 0.19  772 7.063 0.03 
Ever told you had heart 
attack 
0 — —  747 — —  755 1.567 0.46  772 4.493 0.10 
Ever told you had a 
stroke 
0 — —  747 5.737 0.06  756 1.378 0.50  773 15.933 <0.001 
Abbreviation: df, degrees of freedom 
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 50-59  60-69  70-79  80 
Outcome N 
χ2 with 
2 df 
P  N 
χ2 with 
2 df 
P  N 
χ2 with 
2 df 
P  N 
χ2 with 
2 df 
P 
Ever told you had high 
blood pressure 
761 15.968 <0.001  837 3.576 0.17  489 2.386 0.30  306 3.863 0.14 
Told had high blood 
pressure >2 times 
331 3.158 0.21  498 4.527 0.10  302 0.735 0.69  203 0.483 0.78 
Taking prescription for 
hypertension 
331 0.335 0.85  502 4.62 0.10  304 1.711 0.42  208 0.352 0.84 
Now taking prescribed 
medicine for high blood 
pressure 
312 0.004 >0.99  476 5.712 0.06  290 1.445 0.48  203 1.199 0.55 
Doctor told you -high 
cholesterol level 
750 2.236 0.33  832 3.362 0.19  483 0.435 0.80  301 4.832 0.09 
Told to take prescription 
for cholesterol 
652 0.138 0.93  760 3.072 0.22  455 0.072 0.96  280 0.802 0.67 
Ever told had congestive 
heart failure 
760 4.540 0.10  834 5.931 0.05  485 15.707 <0.001  307 0.034 0.98 
Ever told you had 
coronary heart disease 
759 8.306 0.02  831 3.085 0.21  481 4.892 0.09  303 1.467 0.48 
Ever told you had 
angina/angina pectoris 
759 9.995 0.007  836 13.784 0.001  486 0.547 0.76  302 2.102 0.35 
Ever told you had heart 
attack 
761 13.128 0.001  837 9.013 0.01  488 3.008 0.22  304 1.237 0.54 
Ever told you had a stroke 760 10.116 0.006  836 1.315 0.52  489 5.743 0.06  307 1.596 0.45 
Abbreviation: df, degrees of freedom 
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Table 5. Cardiovascular Outcomes by Race 
 Mexican American  Other Hispanic  Non-Hispanic White 
Outcome N χ2 with 
2 df 
P 
 
N χ2 with 2 df P 
 
N χ2 with 2 
df 
P 
Ever told you had high blood pressure 968 0.694 0.71 
 
658 5.188 0.08 
 
1730 1.641 0.44 
Told had high blood pressure >2 times 287 5.771 0.06 
 
223 3.595 0.17 
 
614 3.373 0.18 
Taking prescription for hypertension 289 1.704 0.43 
 
223 17.686 <0.001 
 
620 0.622 0.73 
Now taking prescribed medicine for high blood 
pressure 
251 5.257 0.07 
 
195 6.911 0.03 
 
556 6.791 0.03 
Doctor told you -high cholesterol level 957 1.926 0.38 
 
654 3.204 0.20 
 
1720 11.264 0.004 
Told to take prescription for cholesterol 614 3.465 0.18 
 
488 2.464 0.29 
 
1370 1.698 0.43 
Ever told had congestive heart failure 842 0.226 0.89 
 
602 2.697 0.26 
 
1605 0.424 0.81 
Ever told you had coronary heart disease 839 2.224 0.33 
 
601 0.698 0.70 
 
1599 1.503 0.47 
Ever told you had angina/angina pectoris 843 0.850 0.65 
 
599 0.358 0.84 
 
1604 6.831 0.03 
Ever told you had heart attack 843 0.328 0.85 
 
604 0.568 0.75 
 
1605 0.025 0.99 
Ever told you had a stroke 842 4.817 0.09 
 
604 0.686 0.71 
 
1608 0.608 0.74 
Abbreviation: df, degrees of freedom 
Abbreviation: df, degrees of freedom 
 
 Non-Hispanic Black  Non-Hispanic Asian  Other, including multiracial 
Outcome N 
χ2 with 
2 df 
P  N 
χ2 with 2 
df 
P  N 
χ2 with 2 
df 
P 
Ever told you had high blood pressure 1071 2.309 0.32  545 0.334 0.85  194 6.954 0.03 
Told had high blood pressure >2 times 447 0.157 0.92  125 1.185 0.55  72 0.657 0.72 
Taking prescription for hypertension 449 2.850 0.24  126 2.680 0.26  73 2.571 0.2877 
Now taking prescribed medicine for high blood 
pressure 
414 7.359 0.02  105 4.171 0.12  62 0.210 0.90 
Doctor told you -high cholesterol level 1066 16.584 <0.001  544 4.428 0.11  194 9.859 0.007 
Told to take prescription for cholesterol 802 2.355 0.31  394 0.712 0.70  141 7.976 0.02 
Ever told had congestive heart failure 957 8.537 0.01  488 4.543 0.10  168 3.405 0.18 
Ever told you had coronary heart disease 954 3.952 0.14  488 3.991 0.14  167 1.075 0.58 
Ever told you had angina/angina pectoris 956 4.363 0.11  488 6.493 0.04  167 0.425 0.81 
Ever told you had heart attack 956 9.206 0.01  489 7.362 0.02  167 0.905 0.64 
Ever told you had a stroke 957 0.351 0.84  489 0.756 0.69  168 0.786 0.68 
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Moreover, ORs with 95% CIs were calculated from logistic regression models for 
estimating the effects of exposure to SHS on cardiovascular outcomes. 
In Model 1 (Table 6), compared to nonsmokers not exposed to SHS, secondhand smokers 
had statistically significant association between exposure to SHS and both hypertension and high 
cholesterol levels. Secondhand smokers are 43% more likely to report being told to take 
prescribed medication for hypertension and twice as likely to report that they were taking 
medication for hypertension during the time they answered the questionnaire. Also, secondhand 
smokers are 31% more likely to report that they were told by a physician about having high 
cholesterol levels, and 23% more likely to report taking medication for cholesterol levels. 
Additionally, Model 1 found a statistically significant association between exposure to SHS and 
a reduced likelihood of angina (OR 0.545; 95% CI [0.361, 0.824]) but there was no other 
statistically significant likelihood of having other types of CVDs when exposed to SHS. 
Furthermore, compared to nonsmokers exposed to SHS, smokers are 41.5% more likely 
of having high cholesterol and there was statistically significant association between smoking 
and high cholesterol levels. However, there was no statistically significant association between 
smoking and any of the other CVD outcomes that were examined through Model 1. 
Nagelkerke’s R2 were also calculated for Model 1 which is a measure of the model fit that 
range from 0.00 to 1.00. The values in Model 1 were between 0% and 2% which indicate that 
there are 98% unaccounted variables for the model’s variability and fit. This model was not a 
good fit for the data. 
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Table 6. Unadjusted odds ratios and 95% confidence intervals (CIs) for cardiovascular study 
outcomes. 
Cardiovascular Outcomes 
Nagelkerke's 
R2 
Nonsmokers Exposed to 
Secondhand Smoke 
Smokers 
ORa 95% CI ORa 95% CI 
Ever told you had high blood pressure 0.000 0.908 0.783, 1.052 0.980 0.849, 1.130 
Told had high blood pressure >2 times 0.002 0.923 0.682, 1.250 1.172 0.884, 1.553 
Taking prescription for hypertension 0.007 1.430 1.008, 2.029 0.829 0.557, 1.233 
Now taking prescribed medicine for high 
blood pressure 
0.021 2.099 1.508, 2.922 1.189 0.831, 1.702 
Doctor told you -high cholesterol level 0.007 1.317 1.130, 1.535 1.415 1.129, 1.641 
Told to take prescription for cholesterol 0.002 1.229 1.031, 1.467 1.052 0.888, 1.247 
Ever told had congestive heart failure 0.006 0.699 0.482, 1.014 0.609 0.426, 0.871 
Ever told you had coronary heart disease 0.000 0.905 0.640, 1.281 1.039 0.722, 1.495 
Ever told you had angina/angina pectoris 0.009 0.545 0.361, 0.824 1.071 0.641, 1.790 
Ever told you had heart attack 0.003 0.719 0.517, 1.000 0.805 0.572, 1.134 
Ever told you had a stroke 0.003 0.704 0.495, 1.003 0.965 0.652, 1.427 
aNonsmokers not exposed to secondhand smoke are the reference group. 
Model 2 (Table 7) adjusted the ORs and 95% CI for CVD study outcomes by gender, 
race/ethnicity, and age groups. Compared to nonsmokers not exposed to SHS, secondhand 
smokers were 55% more likely to take prescribed medication for hypertension and 21% more 
likely having high cholesterol levels. Additionally, secondhand smokers were significantly less 
likely to report hypertension, congestive heart failure, CHD, angina, heart attack, and stroke. 
Furthermore, compared to nonsmokers exposed to SHS, smokers were 21% more likely of 
having high cholesterol and smokers were 43% less likely for reporting heart failure. 
Like Model 1, Nagelkerke’s R2 were also calculated for Model 2. However, Model 2 had 
a much better model fit compared to Model 1. All the values in Model 2 were between 4% and 
32%. Although Model 2 had higher values than Model 1, Nagelkerke’s R2 showed that Model 2 
still did not account for 68% of the variables for the model’s variability and fit; however, it is 
still considered a moderate fit that improved the fit of Model 1. 
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Table 7. Adjusteda odds ratios and 95% confidence intervals (CIs) for CVD study outcomes. 
Outcomes 
Nagelkerke's 
R2 
Nonsmokers Exposed to 
Secondhand Smoke 
Smokers 
AORa,b 95% CI AORa,b 95% CI 
Ever told you had high blood pressure 0.314 0.768 0.645, 0.914 0.803 0.677, 0.951 
Told had high blood pressure >2 times 0.042 0.921 0.664, 1.278 1.181 0.883, 1.580 
Taking prescription for hypertension 0.285 1.060 0.697, 1.612 0.698 0.442, 1.102 
Now taking prescribed medicine for high 
blood pressure 
0.156 1.554 1.066, 2.265 1.098 0.749, 1.610 
Doctor told you -high cholesterol level 0.272 1.213 1.017, 1.446 1.206 1.019, 1.428 
Told to take prescription for cholesterol 0.324 0.966 0.783, 1.191 0.905 0.742, 1.105 
Ever told had congestive heart failure 0.195 0.462 0.307, 0.696 0.568 0.390, 0.828 
Ever told you had coronary heart disease 0.231 0.585 0.397, 0.862 0.929 0.632, 1.364 
Ever told you had angina/angina pectoris 0.119 0.421 0.269, 0.659 1.007 0.596, 1.699 
Ever told you had heart attack 0.201 0.489 0.339, 0.706 0.730 0.509, 1.048 
Ever told you had a stroke 0.124 0.543 0.369, 0.798 0.934 0.624, 1.399 
aAdjusted for gender, race/ethnicity, and age groups. 
bNonsmokers not exposed to secondhand smoke are the reference group. 
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DISCUSSION 
The purpose of this study was to assess the distribution and likelihood of CVDs in 
nonsmokers exposed to SHS. It was originally hypothesized that nonsmokers exposed to SHS 
would have similar likelihood of having CVDS compared to firsthand smokers. The results 
showed that secondhand smokers were significantly more likely to take medication for 
hypertension and having high cholesterol levels compared to nonsmokers.  
Based on the results adjusted by demographics in Model 2, this study showed that SHS 
exposure in self-reported nonsmokers was significantly associated with higher likelihood of 
hypertension and cholesterol levels. Both hypertension and cholesterol levels were examined 
using two types of questions. While the first set of questions asks participants if they were told 
before that they have high blood pressure or high cholesterol levels, the second set of questions 
asks participants about medication use for either condition. Results showed that, compared to 
nonsmokers not exposed to SHS, secondhand smokers had significantly higher likelihood of 
taking prescribed medication for hypertension and having high cholesterol levels. However, 
these results were inconsistent with the results of the other questions about hypertension and 
cholesterol levels as they showed no statistically significant association between exposure to 
SHS and having hypertension (OR 0.921; 95% CI [0.664, 1.612]) or taking medication for high 
cholesterol levels (OR 0.966; 95% CI [0.783, 1.191]). Since these answers are self-reported, the 
biases associated with self-report cannot be ruled out. On one hand, recall bias—when 
participants do not recall specific facts or events related to their medical records—can be a result 
of recall error and are common in epidemiology and medical research (Althubaiti, 2016). On the 
other hand, social desirability bias may also play a role: participants answer questions how they 
think the researcher would like them to answer. Social desirability bias is also ubiquitous in 
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epidemiology research especially when researchers are using data based on survey or 
questionnaire and do not have a way to know if participants underestimate or overestimate their 
answers (Althubaiti, 2016). 
Few previous studies have explored the effects of SHS on hypertension, although these 
studies are consistent with the our results, they were gender-specific and typically involved a 
small sample size (Flouris et al., 2008; Li et al., 2015; Mahmud & Feely, 2004). Also, most of 
these studies found that males are more likely to have hypertension than females (Flouris et al., 
2008; Mahmud & Feely, 2004). However, other studies that used larger datasets supported our 
results (Kim et al., 2019; Park et al., 2018; Yang et al., 2017). On one hand, Kim and 
collaborators (2019), examined the association between SHS exposure and hypertension in 
106,268 Korean nonsmokers using both self-reported questionnaire and urine cotinine levels, 
similar to our methods. However, they also used an average of two blood pressure measurements 
and antihypertensive medication intake to examine the association between SHS and 
hypertension. The results concluded that there was a significant association between SHS 
exposure and hypertension even with lower levels of frequent and duration of SHS exposure (OR 
1.16; 95% CI [1.05, 1.24]) (Kim et al., 2019). 
Similarly, Park and collaborators (2018), using data from the Korean National Health and 
Nutrition Examination Survey (KNHANES) V 2010-2012, examined the association between 
SHS exposure and hypertension in 10,532 (8987 women and 1545 men) never smokers. They 
used duration of SHS exposure, blood pressure measurements, and antihypertensive medication 
intake to define the exposure groups. They concluded that there was a significant association 
between SHS exposure and hypertension in women only (adjusted OR 1.50; 95% CI [1.10, 
2.04]) (Park et al., 2018). Additionally, in another study that included more than 5 million 
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females along with their husbands from the National Free Pre‐pregnancy Checkup Projects 
conducted across 31 provinces in China in 2014 examined the association between SHS 
exposure and hypertension. The data were collected using face-to-face interviews and serum 
cotinine levels to define the exposure groups. The investigators found statistically significant 
association between SHS exposure and hypertension in males (OR 1.28; 95% CI [1.27, 1.30]), 
females (OR 1.53; 95% CI [1.30, 1.79]), and mix group of both females and males (OR 1.50; 
95% CI [1.36, 1.67]) (Yang et al., 2017). With the literature supporting the results of the present 
study, it can be concluded that hypertension is significantly associated with exposure to SHS in 
males’ nonsmokers. Thus, nonsmokers who reduce their exposure to SHS reduce their odds of 
developing hypertension. 
Furthermore, previous studies have examined the impact of SHS exposure on cholesterol 
levels in both animal and human studies (Moffatt et al., 2004; Valkonen & Kuusi, 1998; Yuan et 
al., 2007). However, similar to the previous studies reporting hypertension outcomes, most 
studies examined small sample sizes and showed negative effects of SHS exposure at the cellular 
levels that decrease HDL and increase LDL cholesterol (Valkonen & Kuusi, 1998; Yuan et al., 
2007). Although the present study examined self-reported hypercholesterolemia and medication 
intake in general, it still adds value to the current literature on the association between SHS 
exposure and cholesterol levels due to the analysis of a large sample size of a human population. 
The increased likelihood of nonsmokers exposed to SHS to develop high cholesterol levels might 
be due to the negative effect of SHS at the cellular level. For example, it has been established 
that exposure to SHS can cause endothelial dysfunction which can lead to the development of 
atherosclerosis (Glantz & Parmley, 2001; Otsuka et al., 2001). Atherosclerosis is associated with 
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both hypertension and hyperlipidemia (Alexander, 1995). Therefore, exposure to SHS has an 
impact at the cellular level that can lead to further advance the severity of different CVD types. 
Surprisingly, compared to nonsmokers, secondhand smokers are significantly less likely 
of having congestive heart failure CHD, angina, heart attack, and stroke. Although, these results 
contradict the current literature regarding stroke and heart attack, they are considered accurate 
due to the fact that 26% (N=356) of nonsmokers are in the 10-19 years old and 15% (N= 206) are 
in the 20-29 years old group. Typically, these age groups do not develop higher rates of CVDs 
such as CHD, angina, heart attack, and stroke. Additionally, our results do not account for the 
duration of SHS exposure in each age group. These two conditions make a strong argument for a 
dose-response association that cannot be observed in samples with a high proportion of youth, as 
it is the case. 
Limitations 
Several limitations of the study are worth noting. First, there is a possibility of self-
reporting biases, such as social desirability and recall biases (Althubaiti, 2016). Second, a large 
number of participants were excluded from the study due missing variables on SHS exposure and 
CVDs. Third, although the proposed demographic-adjusted Model 2 found some differences 
compared to crude Model 1, the overall model fit (Nagelkerke’s R2) was relatively low for both. 
This means that there are still other variables unaccounted for both models’ variability and fit. 
Those unaccounted variables—such as other health conditions, obesity, genetic composition, 
socioeconomic status (SES), and duration of exposure to secondhand smoke—might have further 
mediation and moderation effects that were not considered in the models. Therefore, future 
studies should consider exploring how other health conditions related to CVDs may attenuate or 
increase the magnitude of the association of SHS with CVDs. 
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Despite these limitations aside, there are notable strengths in this study. First, to the best 
of our knowledge, this is the first study to use the NHANES database to explore the association 
between exposure to SHS and cardiovascular outcomes. The NHANES database included a large 
sample size which is a representative of the demographics in the United States. Second, the 
present study used cotinine measurements to define the three smoker groups including the 
nonsmokers exposed to secondhand smoke in addition to self-reported responses. Using the 
cotinine levels yields an accurate cut-off value to separate the three smoker groups and reduce 
the self-report biases of participants regarding exposure to SHS. Thus, this study further 
advances research on secondhand smoke and cardiovascular disease. Last, this study used a solid 
and widely accepted methodology to investigate both distributional assumptions through chi-
square test and strength of association through logistic regression. 
Implications for Research and Policy 
Future studies should use matched data from secondary sources that explore exposure to 
SHS and cardiovascular outcomes to analyze change over time. This could highlight the effects 
of changes in policies that impact smoking bans in public places as there are 12 states in the 
United States that do not have 100% smoke-free state law (American Nonsmokers' Rights 
Foundation, 2020). Future research should also target the effects of variables not accounted for in 
this study, such as other health conditions, obesity, genetic composition, SES, and duration of 
exposure to secondhand smoke on the cardiovascular outcomes. This study only determined 
whether CVDs were more likely after exposure to SHS but was not able to determine a dose-
response by any of the above variables. 
Furthermore, there are 28 states in the United States that have statewide comprehensive 
smoke-free law in effect, prohibiting smoking in all indoor areas of workplaces, restaurants, and 
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bars (American Lung Association, 2020). Multiple studies have looked at the impact of policies 
implication to regulate SHS exposure among nonsmokers in the United States (Farrelly et al., 
2005; Wilson, Shamo, Boynton, & Kiley, 2012). One study based in Michigan, found that urine 
cotinine levels among nonsmoking bar employees decreased from 35.9 ng/ml to a level that 
could not be measured within 2 months after the have statewide comprehensive smoke-free law 
went into effect. Also, the majority of bar employees reported a significant improvement in 
general health and in six respiratory symptoms (Wilson et al., 2012). Another study based in 
New York, found that salivary cotinine levels among nonsmoking adult workers in restaurants, 
bars, and bowling facilities decreased by 85% within 1 year after the smoke-free law went into 
effect 2003 (Farrelly et al., 2005). Therefore, it is important to have statewide smoke-free law in 
effect in every state in the United States to reduce the SHS exposure among nonsmokers which 
will reduce future CVDs. 
Implications for Clinical Practice 
Considering the strong association between exposure to SHS and both hypertension and 
cholesterol levels, clinicians have the opportunity to start educating patients about the impact of 
SHS exposure on their health. Currently, clinicians do not use any screening test to examine SHS 
exposure. Therefore, we can start screening patients for SHS exposure by including question 
about SHS exposure in home, workplaces, and public places. By doing so, clinicians can add this 
information to the patients’ medical history and implement preventive measure. 
Additionally, clinicians can promote behavior modification plans for nonsmokers 
exposed to SHS or have a family history of CVDs. Past research demonstrates that interventions 
focused on promoting healthy diets have proven effective for reducing the risk of hypertension 
and non-fatal CVDs (Jackson et al., 2020). Additional study concluded that physical training 
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have proven to be an effective method for reducing total serum cholesterol levels (Golding, 
2013). Therefore, more evidence-based interventions need to be developed to target behavior and 
lifestyle modifications. Additional research is needed to identify barriers among different 
populations to develop culturally appropriate preventive programs since not all races/ethnicities 
are exposed to SHS equally. 
Clinician should also consider other variables not accounted for in this study that are 
well-known factors for CVDs among nonsmokers exposed to SHS such as other health 
conditions, obesity, genetic composition, and duration of exposure to secondhand smoke. 
Previous studies have proven that individuals with diabetes mellitus at higher risk if developing 
CVDs such as hypertension and  high cholesterol levels (Leon & Maddox, 2015). Additionally, 
obesity is common in patients with diabetes especially Type II diabetes and is associated with an 
increased risk of CVDs (Leon & Maddox, 2015). Thus, other health conditions may affect a 
nonsmoker exposed to SHS health outcomes by increasing the risk of having CVDs. 
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CONCLUSION 
This study demonstrated a statistically significant distribution and likelihood of 
cardiovascular disease after exposure to second-hand smoke. After controlling for age, sex, and 
race/ethnicity, nonsmokers exposed to second-hand smoke had a significantly higher likelihood 
of reporting hypertension and elevated blood cholesterol levels. Additionally, the present study 
addresses a gap in the literature by using a larger sample size from a nationally representative 
survey to generate more generalizable results pertaining to cardiovascular outcomes in 
nonsmokers exposed to second-hand smoke. This study adds to the literature supporting the need 
to develop health interventions to reduce second-hand smoke exposure. Clinicians and 
researchers should educate, respectively, patients and populations exposed to second-hand smoke 
on meaningful, evidence-based ways to reduce their SHS exposure to reduce the burden of 
cardiovascular disease. 
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